Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Cardiac Action Potential
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Jose Vicente1, Lars Johannesen2, Jay W Mason3
1Office of Science and Engineering Laboratories, CDRH, US FDA, Silver Spring, MD, USA; Division of Cardiovascular and Renal Products, Office of New Drugs, CDER, US FDA, Silver Spring, MD, USA; BSICoS Group, Aragón Institute for Engineering Research (I3A), IIS Aragón, University of Zaragoza, Zaragoza, Spain.
No sex differences were found in drug-induced QT interval prolongation, suggesting other factors contribute to higher torsade de pointes risk in women. This study investigated ECG changes from hERG channel blockers.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: